Pfizer aims to make 10-20 million doses of a coronavirus vaccine it is developing with Germany’s BioNtech by the end of 2020 for emergency use should it pass tests, the U.S. drugmaker’s head of vaccines said on Thursday. The companies, whose project relies on messenger RNA technology never before used in an approved vaccine, have dosed the first humans in Germany and hope to begin a U.S. trial soon, pending regulators’ blessing. Pfizer, BioNtech and other companies are racing to develop a vaccine, since there are currently no approved treatments and only mixed results of medicines under study against the virus.
